Published in J Biomed Sci on January 16, 2015
Combination Treatment with Sublethal Ionizing Radiation and the Proteasome Inhibitor, Bortezomib, Enhances Death-Receptor Mediated Apoptosis and Anti-Tumor Immune Attack. Int J Mol Sci (2015) 0.76
Targeting CD146 in combination with vorinostat for the treatment of ovarian cancer cells. Oncol Lett (2017) 0.75
Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov (2006) 14.01
Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res (1996) 6.03
Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A (2002) 4.33
Cross-presentation by dendritic cells. Nat Rev Immunol (2012) 3.95
The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth. EMBO J (1999) 2.23
Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J Immunol (2000) 2.07
Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs (2005) 2.03
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol (2013) 1.99
Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin. Hum Mol Genet (2001) 1.87
Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res (2007) 1.62
Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells. Cell Death Differ (2005) 1.57
Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther (2003) 1.45
Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene Ther (2000) 1.41
Monitoring the trafficking of adoptively transferred antigen- specific CD8-positive T cells in vivo, using noninvasive luminescence imaging. Hum Gene Ther (2007) 1.23
The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis. Leukemia (2009) 1.15
Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment. Clin Cancer Res (2009) 1.14
Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination. J Mol Med (Berl) (2008) 1.04
Vorinostat enhances the antimyeloma effects of melphalan and bortezomib. Eur J Haematol (2009) 1.02
Vorinostat and bortezomib synergistically cause ubiquitinated protein accumulation in prostate cancer cells. J Urol (2012) 0.98
A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916). Pediatr Blood Cancer (2012) 0.94
Immune mechanism of the antitumor effects generated by bortezomib. J Immunol (2012) 0.93
Development of Proteasome Inhibitors as Therapeutic Drugs. J Clin Cell Immunol (2012) 0.90
A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies. Invest New Drugs (2013) 0.89
Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors. Anticancer Res (2012) 0.89
Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study. Invest New Drugs (2013) 0.88
A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors. Invest New Drugs (2013) 0.84